Replicate Bioscience


Launched:

2021

Management:

Nathaniel Wang

Duke Inventor(s):

Herbert Kim Lyerly

 

 

Replicate Bioscience is developing RNA-based treatments for cancer using proprietary Synthetic Replicon for gene delivery (SynRGY) technology to deliver the genetic code of a virally derived RNA molecule.

 

ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience


Success Story